A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.

Saved in:
Bibliographic Details
Title: A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Authors: File DM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC., Abdou Y; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC. Electronic address: Yara_Abdou@med.unc.edu., Force J; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Moore DT; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Anders CK; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Reeder-Hayes K; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Carey LA; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Muss HB; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Perou CM; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Department of Genetics, The University of North Carolina, Chapel Hill, NC., Marcom PK; Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC., Dees EC; Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Source: Clinical breast cancer [Clin Breast Cancer] 2024 Dec; Vol. 24 (8), pp. 683-690. Date of Electronic Publication: 2024 Aug 08.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0666
DOI:10.1016/j.clbc.2024.08.001